News: Allergan Inc (AGN)

AGN on New York Consolidated

235.41USD
5 Mar 2015
Change (% chg)

$-0.27 (-0.11%)
Prev Close
$235.68
Open
$235.68
Day's High
$236.45
Day's Low
$234.69
Volume
1,264,971
Avg. Vol
2,158,508
52-wk High
$236.45
52-wk Low
$115.94

Search Stocks
Select another date:

EU mergers and takeovers (March 5)

BRUSSELS, March 5 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters March 05, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, now click on Related Co Data, now click on Co Events.

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters March 04, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, now click on Related Co Data, now click on Co Events.

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters March 03, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, now click on Related Co Data, now click on Co Events.

Actavis to take Allergan name, reflecting brand-drug focus

NEW YORK - Actavis Plc , a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs.

UPDATE 3-Actavis to take Allergan name, reflecting brand-drug focus

NEW YORK, Feb 18 - Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs.

UPDATE 2-Greenlight Capital scales back on Apple shares ahead of rally

NEW YORK Feb 13 - Hedge fund Greenlight Capital, run by David Einhorn, cut its stake in Apple Inc by 6.2 percent to 8.6 million shares during the fourth quarter, ahead of the iPhone maker's strong rally this year, according to a regulatory filing on Friday.

EU mergers and takeovers (Feb 10)

BRUSSELS, Feb 10 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

What to Watch in the Day Ahead - Wednesday, Feb. 4

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users can register at RT/DAY/US. All times in ET/GMT) Merck & Co is expected to report lower fourth-quarter earnings, hurt by generic competition for its Singulair asthma drug and its Nasonex allergy treatment. Investors will be paying far greater attention to the No. 2 U.S. drugmaker's earnings forecast

How the Actavis deal upended Allergan No. 2's CEO ambitions

NEW YORK - For two decades, Allergan Inc president Doug Ingram labored to transform the Botox-maker from a sleepy eye care upstart to a global aesthetics giant. He was just a few months away from getting the top job when a merger deal with Actavis Plc in November thwarted his ambitions.

Select another date:
Search Stocks